Related Experiment Video
Updated: Feb 6, 2026

Development and Validation of Chromium Getters for Solid Oxide Fuel Cell Power Systems
Published on: May 26, 2019
Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis
1Division of Hematology, Stanford Cancer Institute / Stanford University School of Medicine, 875 Blake Wilbur Drive, Room 2324, Stanford, CA, 94305-5821, USA.
Purpose Of Review:
We discuss recent developments in the treatment of advanced systemic mastocytosis (advSM) with inhibitors of the KIT receptor tyrosine kinase.
Recent Findings:
advSM is a heterogeneous group of neoplasms of poor prognosis characterized by the accumulation of neoplastic mast cells. The canonical KIT D816V mutation is present in approximately 90% of SM patients, and its detection is critical for both diagnosis and therapeutic decision-making. The multikinase/KIT inhibitor midostaurin was recently approved for advSM. This agent can reverse SM-related organ damage and disease symptoms, and decrease the bone marrow mast cell burden and splenomegaly. However, complete remissions are rare and durability of responses is variable. Potent and selective KIT D816V inhibitors including avapritinib (BLU-285) and DCC-2618 have entered clinical trials, and rational combination strategies are under development. The clinical efficacy of KIT inhibitors validate KIT as a key oncogenic driver in mast cell neoplasms. An improved understanding of the genetic heterogeneity beyond KIT will help inform the dynamics of response and relapse.
Insights
Recent advances in treating advanced systemic mastocytosis (advSM) focus on KIT inhibitors. New targeted therapies show promise for managing this rare cancer, though further research is needed.
Area of Science:
- Oncology
- Hematology
- Molecular Biology
Background:
- Advanced systemic mastocytosis (advSM) is a rare, aggressive cancer.
- Neoplastic mast cell accumulation drives advSM.
- The KIT D816V mutation is a key driver in most advSM cases.
Purpose of the Study:
- To review recent developments in treating advSM.
- To discuss the role of KIT receptor tyrosine kinase inhibitors.
Main Methods:
- Review of current literature on KIT inhibitors for advSM.
- Analysis of clinical trial data for approved and investigational therapies.
Main Results:
- Midostaurin, a KIT inhibitor, is approved for advSM, showing efficacy in reducing organ damage and symptoms.
- Newer, selective KIT D816V inhibitors (avapritinib, DCC-2618) are in clinical trials.
- KIT inhibitors confirm KIT's role in mast cell neoplasms.
Conclusions:
- KIT inhibitors represent a significant advancement in advSM treatment.
- Understanding genetic heterogeneity beyond KIT is crucial for optimizing response and managing relapse.
More Related Videos
Related Concept Videos
Reliability and Validity
Feedback Inhibition
Data Validation
Key parameters for method validation include:
Data Validation
Nursing assessment guides are generally based on holistic models rather than medical...
Enzyme Inhibition
Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.

